The CTD² Network and Cancer Systems Biology Consortium organized a virtual symposium series titled “Multidisciplinary Approaches to Understand Cancer Treatment Resistance”. Registration will open in mid-October for all symposium dates; please join us on 11/16, 11/17, 12/2, 12/16, and 12/17. Click here to view the draft agenda.
Study highlights the usage of FDA-approved tyrosine kinase inhibitors for treating leukemia patients with neurotrophic receptor tyrosine kinase mutations.
Integrated analysis of RNA-sequencing, proteomics, and phosphoproteomics data indicate doublecortin like kinase 1 (DCLK1) modulates proteins and pathways associated with cell motility in patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids.
UCSF CTD2 scientists developed a multi-faceted testing framework and demonstrate that analysis of protein networks rather than a single gene identifies synthetic lethal candidates. These candidates are reproducible as they are dependent on genetic and cellular context.